<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-151398</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Juxtapapillary neovascular membrane secondary to idiopathic intracranial hypertension treated with intravitreal bevacizumab: A case report</dc:title>
<dc:description xml:lang="en">Case report: A 48 year-old woman with visual acuity loss in left eye (0.3). Funduscopic examination showed papillary oedema and neovascular membrane in the left eye. All neurological tests were normal, except the lumbar puncture with opening pressure of 35cmH2O, being diagnosed with idiopathic intracranial hypertension (IIH). After four doses of bevacizumab, the visual acuity of the left eye has not improved and is counting fingers. Discussion: Pathogenesis of the juxtapapillary neovascular membrane associated with IIH is not well known. An effect was observed after the anti-VEGF treatment. In our case, there was no improvement after four doses of intravitreal bevacizumab (AU)</dc:description>
<dc:creator>Sanz López, AM</dc:creator>
<dc:creator>Jiménez Escribano, RM</dc:creator>
<dc:creator>Soler Sanchís, MI</dc:creator>
<dc:creator>Hernández Ortega, V</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Mujer de 48 años con pérdida de agudeza visual (AV) en el ojo izquierdo (OI): 0,3. Funduscópicamente presentaba papiledema y membrana neovascular (MNV) en el OI. Todas las pruebas neurológicas fueron normales excepto la punción lumbar con presión de apertura de 35 cmH2O, siendo diagnosticada de hipertensión intracraneal idiopática (HII). Tras 4 dosis de bevacizumab, la AV del OI no ha mejorado y es de cuenta dedos. Discusión: La patogénesis de la MNV asociada a HII no es bien conocida. Se ha visto eficacia con el tratamiento de anti-VEGF. En nuestro caso no hemos conseguido mejora de la AV tras 4 dosis de bevacizumab intravítreo (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;91(5): 250-254, mayo 2016. ilus</dc:source>
<dc:identifier>ibc-151398</dc:identifier>
<dc:title xml:lang="es">Membrana neovascular coroidea yuxtapapilar secundaria a hipertensión intracraneal idiopática tratada con bevacizumab intravítreo: a propósito de un caso</dc:title>
<dc:subject>^d27865^s22067</dc:subject>
<dc:subject>^d55974^s22031</dc:subject>
<dc:subject>^d27865^s22016</dc:subject>
<dc:subject>^d55974^s22078</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d9582^s22054</dc:subject>
<dc:subject>^d55974^s22073</dc:subject>
<dc:subject>^d9582^s22067</dc:subject>
<dc:subject>^d21052^s22012</dc:subject>
<dc:subject>^d21052^s22067</dc:subject>
<dc:subject>^d21052^s22016</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d24366^s22031</dc:subject>
<dc:subject>^d27865^s22053</dc:subject>
<dc:type>article</dc:type>
<dc:date>201605</dc:date>
</metadata>
</record>
</ibecs-document>
